PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
暂无分享,去创建一个
M. Reiss | E. D. de Vries | R. Gregory | S. Vedelaar | H. Timmer-Bosscha | M. L. Lub-de Hooge | T. Oude Munnink | C. Schröder | A. Walenkamp | J. W. Hesselink | Marlous Arjaans | Silke R. Vedelaar | J. Hesselink | H. Timmer‐Bosscha
[1] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[2] M. Korpal,et al. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. , 2010, European journal of cancer.
[3] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[4] Michael Rugaard Jensen,et al. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. , 2010, European journal of cancer.
[5] K. Garber. Companies waver in efforts to target transforming growth factor beta in cancer. , 2009, Journal of the National Cancer Institute.
[6] Erik Sahai,et al. Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.
[7] Xin Lu,et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis , 2009, Nature Medicine.
[8] J. Massagué,et al. Multimodality imaging of TGFβ signaling in breast cancer metastases , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] Johan R de Jong,et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.
[10] J. Parker,et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. , 2009, The Journal of clinical investigation.
[11] A. Grobbelaar,et al. Transforming growth factor β1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance , 2009, Postgraduate Medical Journal.
[12] J. Massagué,et al. TGFβ in Cancer , 2008, Cell.
[13] J. Berzofsky,et al. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF{beta}) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) , 2008 .
[14] S. Wahl,et al. TGF-beta and tumors--an ill-fated alliance. , 2008, Current opinion in immunology.
[15] H. Hollema,et al. In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.
[16] Cornelis F. M. Sier,et al. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients , 2007, British Journal of Cancer.
[17] Brian Bierie,et al. A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.
[18] R. Beroukhim,et al. Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.
[19] Xueyan Duan,et al. PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling , 2006, Cell.
[20] Dean Sheppard,et al. Integrin-mediated activation of latent transforming growth factor β , 2005, Cancer and Metastasis Reviews.
[21] W. Gerald,et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.
[22] R. Boellaard,et al. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] Sanjiv Sam Gambhir,et al. AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.
[24] Justin P. Annes,et al. Making sense of latent TGFβ activation , 2003, Journal of Cell Science.
[25] N. Khalil. TGF-β: from latent to active , 1999 .
[26] M. Hashida,et al. Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice. , 1999, Biochimica et biophysica acta.
[27] M. Reiss,et al. Transforming growth factor-β in breast cancer: A working hypothesis , 1997, Breast Cancer Research and Treatment.
[28] Anita B. Roberts,et al. Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .
[29] M. Sporn,et al. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. , 1990, The Journal of clinical investigation.
[30] S. Mirzadeh,et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.
[31] R. Coffey,et al. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. , 1987, The Journal of clinical investigation.
[32] de Elisabeth G. E. Vries,et al. 89Zr-bevacizumab PET imaging in renal cell carcinoma patients , 2010 .
[33] Brian Bierie,et al. A delicate balance: TGF-beta and the tumor microenvironment. , 2007, Journal of cellular biochemistry.
[34] M. Weller,et al. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. , 2006, Current pharmaceutical design.
[35] D. Rifkin,et al. Making sense of latent TGFbeta activation. , 2003, Journal of cell science.
[36] C. Knabbe,et al. TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples , 2001 .
[37] N. Khalil. TGF-beta: from latent to active. , 1999, Microbes and infection.
[38] M. Reiss,et al. Transforming growth factor-beta in breast cancer: a working hypothesis. , 1997, Breast cancer research and treatment.
[39] S. Markowitz,et al. Tumor suppressor activity of the TGF-beta pathway in human cancers. , 1996, Cytokine & growth factor reviews.